Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PP 1131

Drug Profile

PP 1131

Alternative Names: P. aeruginosa phages cocktail - PHAXIAM Therapeutics; PHAGOBURN Pseudomonas phage therapy - PHAXIAM Therapeutics; PP-1131

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pherecydes Pharma
  • Developer PHAXIAM Therapeutics
  • Class Pseudomonas phages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Burn infections

Most Recent Events

  • 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
  • 05 Mar 2021 Discontinued - Phase-I/II for Burn infections in France, Belgium (Topical) (Pherecydes Pharma pipeline, March 2021)
  • 16 Feb 2021 Pherecydes Pharma has patent protection for anti-Pseudomonas aeruginosa and anti-E. Coli phages in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top